Home Cart Sign in  
Chemical Structure| 155-58-8 Chemical Structure| 155-58-8

Structure of Rhapontin
CAS No.: 155-58-8

Chemical Structure| 155-58-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rhapontin is a natural product isolated and purified from the roots of Rhei Rhizoma.

Synonyms: Rhaponiticin; Rhaponticin; trans-Rhapontin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rhapontin

CAS No. :155-58-8
Formula : C21H24O9
M.W : 420.41
SMILES Code : O[C@H]1[C@H](OC2=CC(/C=C/C3=CC=C(OC)C(O)=C3)=CC(O)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Synonyms :
Rhaponiticin; Rhaponticin; trans-Rhapontin
MDL No. :MFCD00010117
InChI Key :GKAJCVFOJGXVIA-DXKBKAGUSA-N
Pubchem ID :637213

Safety of Rhapontin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 1-100 µg/mL 24 hours Evaluation of the effect of Rhapontin on HUVEC viability Nutrients. 2023 Feb 14;15(4):949
HEp-2 cells 10, 20, 40 μg/mL 24 hours Evaluate the cytotoxicity of Rhapontin on HEp-2 cells Vet Res. 2025 Feb 4;56(1):26
HT1080 cells 25, 50, 100 µM 24 hours To evaluate the effect of RA on MMP-9 activity in HT1080 cells, results showed RA markedly suppressed the PMA-induced increase in MMP-9 activity. Int J Oncol. 2018 Sep;53(3):1160-1170
BEAS-2B cells 0–100 µM 24 hours Evaluate the effect of Rhapontin on BEAS-2B cell proliferation, results showed Rhapontin had minimal impact on the proliferation of BEAS-2B cells Front Mol Biosci. 2024 Jun 11;11:1413214
A549 cells 0–100 µM 24 hours Evaluate the inhibitory effect of Rhapontin on A549 cell proliferation, results showed Rhapontin had a concentration-dependent proliferation inhibitory effect on A549 cells with an IC50 of 62 μM Front Mol Biosci. 2024 Jun 11;11:1413214
HUVECs 25, 50, 100 µM 4-12 hours To evaluate the effect of RA on tube formation in HUVECs, results showed RA significantly inhibited tube-like network formation. Int J Oncol. 2018 Sep;53(3):1160-1170
CCRF-CEM 18.05 µM 48 hours Evaluate the cytotoxic and apoptosis-inducing effects of Rhapontin on CCRF-CEM cell line. Results showed Rhapontin significantly reduced cell viability and induced apoptosis. Molecules. 2019 May 17;24(10):1896
CEM/C1 51.54 µM 48 hours Evaluate the cytotoxic and apoptosis-inducing effects of Rhapontin on CEM/C1 cell line. Results showed Rhapontin significantly reduced cell viability and induced apoptosis. Molecules. 2019 May 17;24(10):1896
HL60/MX2 31.51 µM 48 hours Evaluate the cytotoxic and apoptosis-inducing effects of Rhapontin on HL60/MX2 cell line. Results showed Rhapontin significantly reduced cell viability and induced apoptosis. Molecules. 2019 May 17;24(10):1896
HL60/MX1 28.38 µM 48 hours Evaluate the cytotoxic and apoptosis-inducing effects of Rhapontin on HL60/MX1 cell line. Results showed Rhapontin significantly reduced cell viability and induced apoptosis. Molecules. 2019 May 17;24(10):1896
HL60 41.75 µM 48 hours Evaluate the cytotoxic and apoptosis-inducing effects of Rhapontin on HL60 cell line. Results showed Rhapontin significantly reduced cell viability and induced apoptosis. Molecules. 2019 May 17;24(10):1896
MDA-MB231 cells 25, 50, 100 µM 48 hours To evaluate the effect of RA on colony formation in MDA-MB231 cells, results showed RA significantly inhibited anchorage-dependent colony formation. Int J Oncol. 2018 Sep;53(3):1160-1170

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Galleria mellonella larvae Streptococcus suis infection model Injection 10, 20, 40 μg/mL Single dose, observed for 72 hours Evaluate the protective effect of Rhapontin on Galleria mellonella larvae infection Vet Res. 2025 Feb 4;56(1):26
Chick embryos Chick chorioallantoic membrane (CAM) model Topical application 100 µg/embryo Single dose, observed for 3 days To evaluate the effect of RA on angiogenesis in the CAM model, results showed RA significantly inhibited spontaneous and VEGF-induced angiogenesis. Int J Oncol. 2018 Sep;53(3):1160-1170
C57BL/6J mice MPTP-induced Parkinson's disease model Gavage 20 mg/kg/day Once daily, throughout the experimental period Rhapontin ameliorated MPTP-induced gastrointestinal dysfunction and motor symptoms in Parkinson's disease mice by activating NRF2. World J Gastroenterol. 2025 Apr 21;31(15):104875

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.89mL

2.38mL

1.19mL

23.79mL

4.76mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories